Taltz ® (ixekizumab) injektion

För fullständig produktresumé för Taltz® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Taltz® ▼ (ixekizumab): Användning hos patienter med COVID-19 (Coronavirus disease 2019)

Behandling med ixekizumab är förknippad med en ökad frekvens av infektioner. Se produktresumén för Taltz för varningar och kontraindikationer.

Use of Ixekizumab in Patients with COVID-19

At this time, Lilly has not studied the use of ixekizumab in patients with coronavirus disease 2019 (COVID-19) nor in patients at risk of contracting COVID-19.

Specific information related to risk of coronavirus infection in patients treated with ixekizumab is not available.

COVID-19 is an active respiratory infection, which is typically mild and may also lead to acute respiratory distress syndrome which can be lethal. Ixekizumab should not be used during active COVID-19 infection and may be resumed after medical consultation and infection is resolved.1

Ixekizumab Treatment in Patients with Suspected or Confirmed COVID-19 and Initiation of Ixekizumab in High Risk Areas

If COVID-19 is confirmed, ixekizumab should be immediately discontinued and may be resumed after medical consultation and infection is resolved.1

If COVID-19 infection is suspected and signs and symptoms of acute infection occur, the patient should consult with their healthcare provider and seek medical advice for guidance on continuing and initiating ixekizumab treatment.1

The decision on treatment remains at the discretion of prescribing physician.

Infectious Disease Resources

For the most current information regarding the coronavirus, please refer to the websites of local health authorities and/or WHO at WHO Coronavirus disease (COVID-19) outbreak.

Label Information related to Infections in General

Contraindication and Warning

Ixekizumab is contraindicated in patients with clinically important active infections (e. g. active tuberculosis).2

Treatment with ixekizumab is associated with an increased rate of infections such as upper respiratory tract infection, oral candidiasis, conjunctivitis, and tinea infections.

Ixekizumab should be used with caution in patients with clinically important chronic infection. If such an infection develops, monitor carefully and discontinue ixekizumab if the patient is not responding to standard therapy or the infection becomes serious. Ixekizumab should not be resumed until the infection resolves.2

Infections as Adverse Drug Reactions of Ixekizumab

Infections belong to the known adverse drug reactions of ixekizumab:

  • Very common:

    • upper respiratory tract infection (including nasopharyngitis and upper respiratory tract infection)

  • Common:

    • tinea infection

    • herpes simplex (mucocutaneous - defined as events with the preferred terms Oral herpes, Herpes simplex, Genital herpes, Herpes dermatitis, and Genital herpes simplex)

  • Uncommon:

    • influenza*

    • rhinitis

    • oral candidiasis (defined as events with the preferred terms oral candidiasis and oral fungal infection)

    • conjunctivitis*

    • cellulitis (includes staphylococcal and external ear cellulitis, and erysipelas)2

*Adverse drug reactions in patients treated with ixekizumab in the plaque psoriasis and psoriatic arthritis clinical trials were similar with the exception of the frequencies of influenza (common) and conjunctivitis (common) in the psoriatic arthritis clinical trials

Therapeutic Indications

Ixekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.2

Ixekizumab, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.2


1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.


Lilly = Eli Lilly and Company

WHO = World Health Organization

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2020 M02 25

Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss